Triple-negative breast cancer (TNBC) lacks the expression of estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, rendering it unresponsive to endocrine and anti-HER2 targeted therapies. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.